Boston Scientific Targets Asthma – Daily Markets

Boston Scientific Targets Asthma
Daily Markets
Leading medical devices player Boston Scientific Corporation (NYSE:BSX) presented long-term safety data from the Research in Severe Asthma (RISA) trial. The study revealed that patients with severe refractory asthma, when treated with Alair bronchial

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *